Uppsala, 2018-03-12

PRESS RELEASE

QuiaPEG enters into a licensing and commercialization agreement with Xiamen SinoPEG Biotech Ltd

QuiaPEG Pharmaceuticals Holding AB (publ), ”QuiaPEG”, announces today that, through its subsidiary, the company has entered into a licensing and commercialization agreement with the global Chinese company Xiamen SinoPEG Biotech Ltd, ”SinoPEG”, a key player in the pegylation industry for development , manufacturing, marketing and sales of products and services based on QuiaPEG’s release pegylation technology, Uni-Qleaver®.

QuiaPEG and SinoPEG signed a Letter of Intent on 20th December 2017, which was completed today by the signing of a long-term licensing and commercialization agreement.

The agreement gives SinoPEG a non-exclusive license to manufacture, market and sell products and services based on Uni-Qleaver®. Under the agreement, a double-digit royalty will be paid to QuiaPEG on sold products and services. QuiaPEG, for its part, will only pay a single-digit royalty to SinoPEG on revenue from commercial license agreements created through SinoPEG’s marketing efforts. Future license revenue is intended to consist of upfront and milestone payments as well as royalties. In parallel with this agreement, QuiaPEG will seek to carry out its own negotiations with pharmaceutical companies on future licensing agreements concerning Uni-Qleaver®.

The agreement also means that SinoPEG, in addition to sales and marketing, will be responsible for the development and implementation of full-scale manufacturing of Uni-Qleaver®. QuiaPEG thus quickly achieves several time and cost-saving benefits in terms of both reduced investment and time to market. Uni-Qleaver® will immediately be exposed in the important North American market where several of SinoPEG’s current customers are operating. The customer base extends from research-related pharmaceutical companies to major global pharmaceutical companies.

”The agreement is a big step forward towards commercialization for QuiaPEG. SinoPEG is a highly competent, reputable and global player with high manufacturing capacity and many customers. We are convinced that SinoPEG is the right partner in the future and we look forward to launching Uni Qleaver®, especially in the important North American market where SinoPEG already has a strong presence, ” says Marcus Bosson, CEO, QuiaPEG.

”We are very pleased to enter into long-term strategic and commercial cooperation with QuiaPEG, whose unique and patented platform, Uni-Qleaver®, will complement our existing product range well. We estimate that the potential for Uni-Qleaver® is very large as the market for this type of technology is expected to grow sharply in the next few years, ”says Dr. Chun Zhou, SvP Business Development, SinoPEG.



From the left: Dr. Chun Zhou, SvP Business Development, SinoPEG,
Marcus Bosson, CEO, QuiaPEG and Dr. Stacy Lin, Business Development, SinoPEG

For further information contact:
Marcus Bosson, CEO
Tel: +46 (0) 70 693 12 53
E-mail: marcus.bosson@quiapeg.com
www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided, through the above contact person, for publication on March 12th, 2018.

About QuiaPEG

QuiaPEG Pharmaceuticals Holding AB (publ) is a pharmaceutical development company based on a patented so-called drug delivery platform, Uni-Qleaver®. The company develops improved and patentable forms of drugs under development or already approved by the pharmaceutical authorities. These refined and improved forms of pharmaceuticals are based on the company's unique and patented technology platform. In parallel, efforts are also being carried out to outsource the platform.

About SinoPEG

SINOPEG is a dynamic science company dedicated to developing and manufacturing of poly(ethylene glycol) derivatives (PEGs) for drug pegylation, drug delivery, medical devices, bio-engineering, diagnostic assay development, polymer engineering, and other broad uses in nanotechnology.

With proprietary technologies and state-of-the-art GMP standard manufacturing capability, SINOPEG is capable of supplying small to large quantities of rich selection of PEG derivative products with unique molecular designs (chemical structure, molecular weights (MW)) and exceptional product quality control to serve bio-technology and pharmaceutical companies and research organizations worldwide.

SINOPEG is looking forward to collaborating with our partners to extend product and technology services to include drug pegylation service, conjugation product separation and characterization, and polymer designs for drug delivery systems etc.

SINOPEG is proud collaborator with a number of well-known universities, research institutes and pharmaceutical and biotech companies around the globe.